Press release

Know Labs Announces Racer Technology as Manufacturing Partner

Sponsored by Businesswire

Labs, Inc.
(OTCQB: KNWN) a provider of diagnostic solutions, today
announced Racer
Technology Pte. Ltd.
will manufacture its wearable UBAND Calorie
Counter and later its wearable UBAND Continuous Glucose Monitor (CGM).
Racer Technology, a medical device and wearables manufacturer, is
headquartered in Singapore with factories across Asia.

Racer Technology, led by CEO, Willy Koh, has state of the art
manufacturing processes and a workforce trained in the latest
manufacturing techniques. It is a valued manufacturer for many of the
world’s leading producers of FDA approved medical devices and wearable
products. Among Racer’s customers are several prominent companies
including Philips, Proctor & Gamble, Medtronic and Boston Scientific.
They were also the manufacturer of the first million Fitbit wearables.

Know Labs CEO, Phil Bosua, said of the Racer relationship, “We are very
excited to have Racer as our manufacturer. We met with them at their
headquarters and visited their factories in Singapore and Indonesia.
Racer’s reputation for delivering top of the line products, their
intense quality control along with their enthusiasm for the Know Labs
product pathway make them a perfect fit for us.”

Racer CEO, Willy Koh, stated, “Know Labs is delivering the first
significant technological innovation we have seen in a long time. We are
eager to begin working with them to manufacture wearable products that
will have a positive impact on people’s health and wellness.”

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade under the stock
symbol “KNWN.” The company’s technology directs structured light or
radio waves through a substance or material to capture a unique
molecular signature. The Company refers to these signatures as ChromaID™
and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or
diagnose substance markers or biomarkers that may be invisible to the
human eye. ChromaID and Bio-RFID scanner modules can be integrated into
a variety of wearable, mobile or bench-top form factors. This patented
and patent pending, award-winning technology makes it possible to
effectively conduct analyses that could only previously be performed by
invasive and/or large and expensive lab-based tests. For more
information on Know Labs, visit the company’s website at

About Racer Technology Pte. Ltd.

Racer Technology is headquartered in Singapore with factories in
Singapore, Indonesia and Malaysia and offices in Singapore and the USA.
One of the leading medical health care manufacturers in the world, they
have been the manufacturing partner of several prominent companies,
including Fitbit, Proctor & Gamble, Philips, Medtronic, Boston
Scientific, Medela, Applied Biosystems, among others. Racer Technology
provides high quality material and uncompromising quality through a
quality management system, and Good Manufacturing Practices, that comply
with international standards. Quality management is maintained through
advanced statistical techniques, coupled with the latest technological
equipment. Racer Technology holds ISO 9001:2015, ISO 13485:2016, ISO
17712:2013, is an FDA Registered Facility, and is UL certified. Racer
Technology meets international product certification compliance
including FDA Classes, EU Medical Device Directive 2007/47/EC,
International Standards (ISO), European Standards (IEC, EN, BS, etc.),
National Standard (AAMI, ASTM, ANSI, etc.), and Safety and Conformity
marks (CE, UL, CCC, IC, IECEE, etc.). Racer adheres to Factory 4.0
standards as a common practice and trains its employees on the newest
advances in manufacturing operations. For more information on Racer
Technology, visit the company’s website at

Safe Harbor Statement

This release contains statements that constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements appear in a number of places in this release
and include all statements that are not statements of historical fact
regarding the intent, belief or current expectations of Know Labs, Inc.,
its directors or its officers with respect to, among other things: (i)
financing plans; (ii) trends affecting its financial condition or
results of operations; (iii) growth strategy and operating strategy. You
can identify these statements by the use of the words “may,” “will,”
“could,” “should,” “would,” “plans,” “expects,” “anticipates,”
“continue,” “estimate,” “project,” “intend,” “likely,” “forecast,”
“probable,” “potential,” and similar expressions and variations thereof
are intended to identify forward-looking statements. Investors are
cautioned that any such forward-looking statements are not guarantees of
future performance and involve risks and uncertainties, many of which
are beyond Know Labs, Inc.’s ability to control, and actual results may
differ materially from those projected in the forward-looking statements
as a result of various factors. These risks and uncertainties also
include such additional risk factors as are discussed in the Company’s
filings with the U.S. Securities and Exchange Commission, including its
Annual Report on Form 10-K for the fiscal year ended September 30, 2018,
Forms 10-Q and 8-K, and in other filings we make with the Securities and
Exchange Commission from time to time. These documents are available on
the SEC Filings section of the Investor Relations section of our website
The Company cautions readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made. The
Company undertakes no obligation to update any forward-looking statement
to reflect events or circumstances after the date on which such
statement is made.